Abbott reports fourth-quarter sales that miss analysts’ estimates.

Abbott Labs stock drops on sales miss and weak guidance for 2026, analyst cuts price target but maintains rating.

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

Analysts' ratings for Abbott Laboratories (NYSE:ABT) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The following table encapsulates their recent ratings, offering a ...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

If you are wondering whether Abbott Laboratories' current share price around US$121.76 offers solid value, you are not alone.

The medical-products maker’s shares tumbled after its quarterly profit and sales underwhelmed investors.

Abbott Laboratories (NYSE:ABT) has significantly outperformed the broader S&P 500 index this year, with its stock price rising 18% compared to the S&P 500’s 6% gain. This strong performance stems from ...

ABT's Q4 earnings meet estimates but revenues miss, sending shares down as strong device growth is offset by weaker nutrition and diagnostics sales.

Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

9 analysts have shared their evaluations of Abbott Laboratories (NYSE:ABT) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table provides a quick ...